Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PPCB
PPCB logo

PPCB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Propanc Biopharma Inc (PPCB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.920
1 Day change
-4.24%
52 Week Range
234.000
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

PPCB is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock is trading at a deeply distressed penny-stock level, lacks supportive proprietary buy signals, and is facing a reverse split event that usually reflects fundamental pressure and listing compliance issues. Even with an oversold RSI, the broader trend is bearish and the setup is better suited to speculation than long-term investing. Based on the data provided, I would avoid buying and prefer to stay out.

Technical Analysis

The technical picture is bearish. MACD histogram is negative and expanding, showing downside momentum is still building. RSI_6 at 19.168 indicates the stock is oversold, but oversold alone does not make it a buy when trend confirmation is weak. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend across short, medium, and long-term frames. Key levels show pre-market price 0.0731 is just above S1 at 0.0727 and well below the pivot at 0.0892, suggesting price remains near support rather than in a confirmed reversal. The recent pattern-based forecast suggests only modest short-term upside, but not enough to override the weak trend.

Positive Catalysts

  • The only clear near-term positive catalyst is the oversold RSI, which can sometimes precede a short bounce. The stock is also showing a small pre-market gain of 0.14%, and the pattern-based projection suggests possible short-term upside over the next week and month. However, these are weak technical catalysts rather than strong fundamental drivers.

Neutral/Negative Catalysts

  • The biggest negative catalyst is the announced 1-for-25 reverse stock split effective May 18, 2026, which signals continuing listing-compliance pressure and usually weak underlying market confidence. MACD is bearish and worsening, moving averages are firmly negative, and the stock remains below the pivot. Hedge funds and insiders are neutral with no meaningful accumulation signals. No recent politician or influential figure trading was reported. No congress trading data is available.

Financial Performance

No financial snapshot was available because of a data error, so the latest quarter season and growth trends cannot be assessed from the provided information.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data was provided, so there is no evidence of a favorable Wall Street upgrade trend. From the available information, Wall Street sentiment appears neutral to negative: there are no insider or hedge fund buying trends, and the reverse split news is a strong bearish sign. I do not see a bullish pros view strong enough to support a buy decision.

Wall Street analysts forecast PPCB stock price to rise
Analyst Rating
0
Wall Street analysts forecast PPCB stock price to rise
Buy
Hold
Sell
0
Current: 2.005
sliders
Low
0
Averages
0
High
0
0
Current: 2.005
sliders
Low
0
Averages
0
High
0
No data

No data

People Also Watch